1. Home
  2. PESI vs SABS Comparison

PESI vs SABS Comparison

Compare PESI & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Perma-Fix Environmental Services Inc.

PESI

Perma-Fix Environmental Services Inc.

HOLD

Current Price

$10.67

Market Cap

243.9M

Sector

Industrials

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.86

Market Cap

201.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PESI
SABS
Founded
1990
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
243.9M
201.4M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
PESI
SABS
Price
$10.67
$3.86
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$9.80
AVG Volume (30 Days)
171.5K
730.1K
Earning Date
03-24-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
43.61
N/A
EPS
N/A
N/A
Revenue
$642,000.00
N/A
Revenue This Year
$71.17
N/A
Revenue Next Year
$51.60
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.25
$1.00
52 Week High
$16.50
$6.60

Technical Indicators

Market Signals
Indicator
PESI
SABS
Relative Strength Index (RSI) 29.42 47.18
Support Level $10.04 $3.54
Resistance Level $12.37 $4.16
Average True Range (ATR) 0.81 0.28
MACD -0.20 -0.02
Stochastic Oscillator 20.43 11.64

Price Performance

Historical Comparison
PESI
SABS

About PESI Perma-Fix Environmental Services Inc.

Perma-Fix Environmental Services Inc is a provider of both nuclear services and the management of nuclear and mixed waste. The company operates through two segments: The treatment segment offers nuclear, low-level radioactive, Mixed, hazardous and non-hazardous waste treatment, processing and disposal services, and the Services segment which generates the majority of the revenue, provides on-site waste management services to commercial and government customers, technology-based services, construction, logistics, and transportation services among others.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: